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Atrial fibrillation (AF) is the most common cardiac arrhythmia en-
countered in clinical practice. Despite the frequent coexistence
with coronary artery disease (CAD), the prognostic independent im-
plication of AF in patients with stable CAD remains controversial.
Our aim was to perform a pairwise meta-analysis of adjusted ob-
servational studies comparing cardiovascular outcomes in patients
with stable CAD with and without concomitant AF, in search of
AF-specific prognostic implications. We performed random effect
meta-analysis of binary outcome events in studies comparing sta-
ble CAD patients with versus without AF providing risk estimates ad-
justed for confounding variables. Literature search was performed in
PubMed/MEDLINE and Google Scholar. Death was the primary end-
point of the analysis, while myocardial infarction, coronary revascu-
larization and stroke secondary endpoints. 5 studies were included
in the meta-analysis, encompassing a total of 30230 stable CAD pa-
tients (2844 with AF, 27386 without AF). Stable CAD patients with AF
presented an independent increased risk of death (HR 1.39, 95% CI:
1.17–1.66) and stroke (HR 1.88, 95% CI: 1.45–2.45) compared to those
without AF. Instead, risk of myocardial infarction (HR 0.90, 95% CI:
0.66–1.22) and coronary revascularization (HR 0.96, 95% CI: 0.79–
1.16) did not differ in stable CAD patients with and without the ar-
rhythmia. In patients with stable CAD, AF exerts an independent
negative prognostic effect, increasing the risk of death and stroke.
However, the small number of eligible studies included in this anal-
ysis highlights the astonishing lack of data regarding prognostic im-
plications of concomitant AF in patients with stable CAD.
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1. Introduction
Atrial fibrillation (AF) is the most common tachyarrhyth-
mia encountered in clinical practice [1]. Due to progressive
population aging, the prevalence of this condition, currently
settled at 2–4% worldwide, is deemed to double in the com-
ing decades [1–4]. Coronary artery disease (CAD) frequently
coexists with AF, and management of these associated con-
ditions can be challenging [5]. In addition, AF may induce
angina-like chest pain and increase markers of myocardial
damage, even in the absence of classical CAD [6].
Despite the frequent coexistence of these two cardiac con-
ditions, the prognostic independent implication of AF in pa-
tients with stable CAD remains controversial. In particular,
although preclinical and clinical evidence suggests that AF it-
self may promote a reduction in coronary blood flow [7–11],
less is known regarding the impact of the arrhythmia in stable
CAD patients in terms of cardiac ischemic outcomes.
The aim of the present systematic review and meta-
analysis of prospective adjusted observational studies is,
therefore, to assess the prognostic independent impact of
concomitant AF on stable CAD patients in terms of mortal-
ity, coronary events, and cerebrovascular events.
2. Methods
This systematic review and meta-analysis was performed
in accordance with the PRISMA [12] and MOOSE [13]
guidelines.
2.1 Search strategy and study selection
PubMed/MEDLINE and Google Scholar databases were
screened for pertinent articles, using the following keywords:
“coronary artery disease”, “stable”, “atrial fibrillation”, “death”,
“myocardial infarction”, “stroke”, “coronary revasculariza-
tion”. The search was ended in May 2019. Two indepen-
dent reviewers (AS and VV) screened the retrieved citations
through the title and/or abstract, and all disparities were re-
solved through consensus. Studies were included if they re-
ported data from observational prospective studies describ-
ing the risk of all cause death (primary outcome) and/or
other cardiovascular outcomes (myocardial infarction, coro-
nary revascularization, stroke) in patients with stable CAD
and AF vs patients without history of the arrhythmia, pro-
vided that the risk estimates were adjusted for possible con-
founding variables. Studies that did not fulfil the aforemen-
tioned study design criteria or in which data were not ad-
equately reported were excluded from the analysis. Risk of
bias evaluation of the included studies was performed using
the Newcastle Ottawa Scale.
Fig. 1. PRISMA flowchart.
2.2 Statistical analysis
Continuous variables and categorical variables were re-
ported as numbers and percentages, respectively. Median
(interquartile range—IQR) was used for the summary statis-
tics. Pairwise meta-analysis of adjusted hazard ratio (HR) of
the evaluated endpoints in stable CAD patients with versus
without AF was performed after logarithmic transformation
using a random-effect model (inverse-variance weighting).
Forest plots for each outcome were reported. Cochran I2
test was used to assess heterogeneity in the included studies.
Funnel plot analysis and Egger’s test for funnel plot asymme-
try were used to assess potential publication bias. Statistical
analyses were performed with R version 4.0.0 (R Foundation
for Statistical Computing, Vienna, Austria).
3. Results
The initial search identified 6888 potential studies: among
these, 6749 were screened for possible inclusion, 6671 were
excluded through title and abstract because not relevant to the
topic, and 78 full-text articleswere carefully reviewed (Fig. 1).
Finally, 5 studies were included in the present systematic re-
view and meta-analysis [14–18], encompassing 30230 stable
CAD patients (2844 with AF, 27386 without AF). Table 1
(Ref. [14–18]) reports main characteristics of the studies, in-
cluding the type of statistical adjustment used to control con-
founding. The median follow-up duration was 4.8 (IQR 4–
4.9) years. Table 2 summarizes pooled baseline features of
the meta-analytic population. The majority of patients were
men (63.4% and 68.0%, in AF and non-AF patients, respec-
tively) and median age was 69.2 and 64.1 years, in AF and
non-AF patients, respectively. Median left ventricular ejec-
tion fraction was 52.8% and 56.6%, in AF and non-AF pa-
tients, respectively. Previous stroke/transient ischemic at-
tach (TIA) history was present in 22.2% and 16.2%, in AF
and non-AF patients, respectively. Previous myocardial in-
farction (MI), percutaneous coronary intervention (PCI) and
coronary artery bypass grafting (CABG) were reported in
21.9% and 27.7%, 25.3% and 28.1%, and 6.8% and 5.2%, for
AF and non-AF patients, respectively. All included studies
showed low risk of bias according to Newcastle Ottawa Scale
(Table 3, Ref. [14–18]).
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Table 1. Main characteristics of the included studies.
Study (first Author, year of publication) Patients—n AF—n (%) Non-AF—n (%) Follow-up (years) Statistical adjustment
Otterstad, 2006 [14] 7665 313 (4.1) 7352 (95.9) 4.9 Adjusted Cox regression
Marte, 2009 [15] 613 57 (9.3) 576 (90.7) 4.0 Adjusted Cox regression
Bouzas-Mosquera, 2010 [16] 17100 619 (3.6) 16481 (96.4) 6.5 Adjusted Cox regression
Rohla, 2015 [17] 1434 146 (10.2) 1288 (89.8) 4.8 Adjusted Cox regression
Han, 2018 [18] 3418 1709 (50.0) 1709 (50.0) 2.2 Adjusted Cox regression
n, number; AF, atrial fibrillation.
Table 2. Pooled baseline clinical features of the study population (30230 patients).
Variables Median value (lower–upper quartile)
AF group Non–AF group
(N:2824) (N:27406)
Demographics
Age (years) 64.3 (63.9–65.9) 69.2 (67.9–70.7) 64.1 (63.3–65.0)
Male sex (%) 67 (62.8–72) 63.4 (62.7–71.9) 68.0 (62.3–72.1)
Coronary risk factors
Hypertension (%) 51.8 (49.4–83.9) 49.1 (49.0–83.6) 52.0 (49.4–84.0)
Smoking (%) 27.6 (20.7–39.7) 16.9 (15.2–24.1) 28.7 (20.9–41.3)
Diabetes (%) 20.7 (15.6–29.7) 16.0 (14.5–29.5) 21.0 (15.7–29.7)
Dyslipidemia (%) 63.8 (56.2–71.2) 60.1 (51.9–62.6) 63.8 (60.0–71.9)
BMI 27.5 (27.4–27.8) 27.3 (26.7–27.7) 27.5 (27.5–27.8)
Comorbidities
Heart failure (%) 8.9 (5.6–18.2) 27.3 (17.2–27.7) 6.8 (4.2–17.2)
Ejection fraction 56.3 (52.6–61.7) 52.8 (50.2–53.4) 56.6 (52.8–62.3)
Previous stroke/TIA (%) 17.0 (12.4–21.5) 22.2 (20–24.3) 16.2 (11.5–20.8)
Peripheral artery disease (%) 10.4 (8.7–12.2) 10.9 (9.2–12.5) 10.2 (8.4–12.0)
Chronic kidney disease (%) 23.4 (16.4–30.5) 30.2 (19.8–40.6) 23.1 (16.1–30.0)
Previous coronary events
MI (%) 27.1 (22.2–39.2) 21.9 (18.4–39.5) 27.7 (22.6–39.4)
PCI* (%) 27.8 (18.5–36.5) 25.3 (16.2–36.7) 28.1 (18.6–36.6)
CABG (%) 5.4 (4.2–6.5) 6.8 (5.3–8.2) 5.2 (4.1–6.4)
Antithrombotic therapy
Antiplatelet agent (%) 89.3 (66.8–98.8) 73.0 (52.5–85.9) 90.0 (79.5–94.7)
Anticoagulant therapy (%) 5.12 (3.98–6.26) 33.9 (29.3–45.5) 3.0 (2.6–3.1)
* Number of patients who had undergone to PCI before enrolment in the study.
BMI, Body Mass Index; CABG, coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary interven-
tion.
All five included studies evaluated the primary outcome,
while two studies reported adjusted risk estimates for stroke,
three for myocardial infarction and two for coronary revas-
cularization. Details on the adjustment performed in each
study are reported in SupplementaryTable 1 in the Supple-
mentary Material Pooled analysis of adjusted observational
results indicates an increased risk of death in stable CAD pa-
tients with concomitant AF, compared to stable CAD pa-
tients without the arrhythmia (HR 1.39, 95% CI: 1.17–1.66).
Low degree of heterogeneity was found for this outcome (I2
= 35%), and funnel plot analysis (Supplementary Fig. 1) did
not suggest potential publication bias (Egger’s test p-value
0.28). Fig. 2 reports the forest plot for the primary out-
come. Focusing on secondary outcomes (Fig. 3 and Supple-
mentary Figs. 2–4), AF independently increased the risk of
stroke in this group of patients (HR 1.88, 95% CI: 1.45–2.45,
I2 = 0%). Instead, risk of myocardial infarction (HR 0.90, 95%
CI: 0.66–1.22, I2 = 25%) and coronary revascularization (HR
0.96, 95% CI: 0.79–1.16, I2 = 0%) did not differ in stable CAD
patients with or without AF.
4. Discussion
The main findings of the present systematic review and
meta-analysis are the following:
• AF independently increases the risk of death in patients
with stable CAD by 39%;
• patients with stable CAD and concomitant AF have
nearly twofold increase in risk of stroke (+88%) compared to
patients with stable CAD without AF;
• AF does not seem to result into an increased risk of
classically defined coronary events (myocardial infarction and
coronary revascularization).
AF and CAD are two frequently coexisting conditions,
sharing common risk factors, such as age, hypertension, dia-
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Fig. 2. Forest plot for the primary outcome (death).
Fig. 3. Forest plots for secondary outcomes (stroke, myocardial infarction and coronary revascularization).
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Table 3. Risk of bias evaluation using the Newcastle-Ottawa
Scale (NOS).
Study (first Author, year of publication)
NOS domains
Selection Comparability Outcome
Otterstad, 2006 [14] **** ** ***
Marte, 2009 [15] **** ** ***
Bouzas-Mosquera, 2010 [16] **** ** ***
Rohla, 2015 [17] **** ** ***
Han, 2018 [18] **** ** **
Asterisks indicate the star rating according to the Newcastle-Ottawa Scale. 
Good quality is definedwith: 3–4 stars in “Selection” and 1–2 stars in “Com-
parability” and 2–3 stars in “Outcome”. Fair quality is defined with: 2 stars
in “Selection” and 1–2 stars in “Comparability” and 2–3 stars in “Outcome”.
Poor quality is defined with: 0–1 stars in “Selection” or 0 stars in “Compa-
rability” or 0–1 stars in “Outcome”.
betes mellitus, sleep apnoea, obesity and smoking [5]. Con-
sidering the increasing life expectancy, these two conditions
are deemed to coexist even more in the near future. It is,
therefore, critical to evaluate the independent impact (net of
possible confounder) that the presence of the most common
atrial arrhythmia exerts in patients with stable CAD. Partic-
ularly, the eventual impact of AF on the risk of future coro-
nary events is still greatly unexplored. The present system-
atic review strongly highlights the unexpected paucity of data
assessing the clinical impact that AF exerts per se on stable
CADpatients: in fact, only 5 studies address the hardest clini-
cal endpoint (death), and even fewer the other cardiovascular
outcomes (stroke, myocardial infarction and coronary revas-
cularization).
The present analysis shows, in any case, that AF has an in-
dependent prognostic influence in patients with stable CAD,
conferring an additional 39% risk of death, as well as an 88%
additional risk of incident stroke. Being CAD a risk factor
for stroke and death per se, this relationship entails an even
greater risk for these complications compared to AF alone.
On the other hand, interestingly, AF does not appear to con-
fer a worse CAD related outcome. However, before drawing
definite conclusion about this relationship, it must be taken
into account the small number of studies included into the
analysis, which could entail statistical underpowering on the
topic.
Future studies are warranted to reach definitive conclu-
sions on this topic. Moreover, evidence is needed investigat-
ing the effect of the AF related “irregularly irregular” rhythm
on the coronary circulation, both in terms of acute hemody-
namic data than potential pro-atherogenic effect.
5. Limitations
First, the observational design of the included studies
carries an inherent risk of unaccounted confounders. In
addition, the lack of patient-level data limited establishing
eventual prognostic implications of the specific AF subtype
(paroxysmal, persistent, permanent). Moreover, data on the
safety profile of a combined therapy with anticoagulant and
antiplatelet agents are missing and considerations on this re-
gard were not possible. Finally, the restricted number of
studies evaluating cardiovascular outcomes other than death,
limits inferential power to detect potentially significant dif-
ferences in these outcomes among groups of interest.
6. Conclusions
In patients with stable CAD AF exerts an independent
negative prognostic effect, increasing the risk of death and
stroke. However, the small number of eligible studies in-
cluded in this analysis highlights the astonishing lack of data
regarding prognostic implications of concomitant AF in pa-
tients with stable CAD, stressing the need for future studies
focused on this topic, as well as on the hemodynamic effects
exerted by the arrhythmia on the coronary circulation.
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